HCPLive

Kynamro Approved for Genetic Condition Tied to Cholesterol

 
WEDNESDAY, Jan. 30 (HealthDay News) -- Kynamro (mipomersen sodium) has been approved by the U.S. Food and Drug Administration to treat homozygous familial hypercholesterolemia (HoFH), a rare inherited condition in which the body can't remove low-density lipoprotein (LDL) cholesterol from the blood, as an addition to lipid-lowering medications and diet.

Many people with HoFH have a heart attack and die before age 30, the FDA said in a news release. HoFH affects approximately one in every one million people in the United States. Kynamro is a once-weekly injection designed to lower creation of blood lipid particles that ultimately form LDL, the agency said.

The drug was clinically evaluated among 51 people with HoFH. Among Kynamro users, LDL levels fell an average of about 25 percent during the first 26 weeks, the FDA said. The drug will carry a "black box" label warning of possible liver abnormalities that could lead to progressive liver disease.

More common side effects noted during clinical testing included injection-site reactions, flu-like symptoms, nausea, headache, and elevated liver enzymes.

Kynamro is produced by Genzyme Corp., of Cambridge, Mass.
 

More Information


Copyright © 2013 HealthDay. All rights reserved.
 
 

Most Popular

Recommended Reading

Researchers from the Division of Endocrinology and Metabolism at the University of California, San Francisco analyzed the impact of virtual consultations on the spectrum and volume of endocrine consults. They measured access to endocrine care and downstream health care utilization. Their results indicate that virtual consultation offers many advantages for endocrinologists.
Type 1 diabetes mellitus is an autoimmune disease in which the body destroys all or part of its own roughly 1 billion β cells and cannot regenerate these critical endocrine components. Researchers have turned their attention to immunotherapies for treatment, postulating that targeting the immune system might restore β-cell function. It appears that combination therapies may be needed since clinical trial results have not met expectations based on animal studies.
Researchers say "scrambler therapy" can be used to treat pediatric complex regional pain syndrome.
An adapted version of the conventional measles vaccine could potentially be effective against the Chikungunya virus.
$vAR$